Rheumatology News

The FDA has granted fast track designation to CB-010, an allogeneic anti-CD19 CAR T-cell therapy from Caribou Biosciences, for refractory systemic lupus erythematosus ahead of a planned phase 1 trial, according to a press release.

Nearly all biologic and targeted synthetic disease-modifying antirheumatic drugs come with infection or malignancy warnings from U.S. or European regulatory agencies, according to a study published in Drug Safety.

In this Healio video exclusive, Leonard Calabrese, DO, chief medical editor of Healio Rheumatology, shouts out key stories in the August issue, including an in-depth cover on language barriers as a major driver of health care disparities.

As part of the ongoing challenge to achieve work-life integration, experts are pursuing creative endeavors and practicing decompression to provide outlets for physicians struggling with burnout.

Retirement planning for physicians is a critical aspect of financial management, given the unique challenges and opportunities they face.

The use of machine learning models to predict treatment response in rheumatoid arthritis is increasing, though approximately 80% show “unclear and high risk of bias,” according to data published in Seminars in Arthritis and Rheumatism.

Clinicians will gather for AIMed24 to meet with industry leaders and innovators and attend keynotes and workshops to discuss the future of AI implementation in medicine, according to information from the meeting organizers.

Attempts to curtail prior authorizations for patients insured by Medicare Advantage plans have failed in back-to-back legislative sessions in 2019 and 2021, but a new bill has some experts hopeful that the third time is a charm.

The FDA has approved an updated label for Gloperba, an oral liquid colchicine formulation, allowing for precision dosing, according to a press release from Scilex Holding Company.

In the third episode of the NSAIDs saga, we focus on COX-2 inhibition! Did the hopes and dreams of selective COX-2 inhibition pan out? What can the rise and fall of VIOXX teach us about physiology?